The UK is setting up a nationwide dementia registry designed to accelerate clinical trial recruitment while collecting real-world evidence once therapies are approved. The approach centers on pre-screening and consent processes to reduce lag between a patient’s eligibility and trial enrollment. The initiative targets both speed and scalability, aligning with a growing need for larger, faster-to-enroll cohorts as Alzheimer’s trials increasingly rely on biomarker-defined populations. For the biotech ecosystem, the registry may improve recruitment predictability and help sponsors manage site timelines and screening logistics more effectively.